[go: up one dir, main page]

HK1039745A1 - 用於改善识别的非典型抗精神病药和乙酰胆碱酯酶 - Google Patents

用於改善识别的非典型抗精神病药和乙酰胆碱酯酶 Download PDF

Info

Publication number
HK1039745A1
HK1039745A1 HK02100158.6A HK02100158A HK1039745A1 HK 1039745 A1 HK1039745 A1 HK 1039745A1 HK 02100158 A HK02100158 A HK 02100158A HK 1039745 A1 HK1039745 A1 HK 1039745A1
Authority
HK
Hong Kong
Prior art keywords
acetylcholinesterase inhibitor
atypical antipsychotic
combination
improving cognition
alzheimer
Prior art date
Application number
HK02100158.6A
Other languages
English (en)
Chinese (zh)
Inventor
Leonce Irma De Nijs Paul
Louis Julien Parys Wim
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HK1039745A1 publication Critical patent/HK1039745A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
HK02100158.6A 1998-10-16 1999-10-12 用於改善识别的非典型抗精神病药和乙酰胆碱酯酶 HK1039745A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98203454.8 1998-10-16
EP98203454 1998-10-16
PCT/EP1999/007804 WO2000023057A2 (fr) 1998-10-16 1999-10-12 Therapie visant a ameliorer la cognition

Publications (1)

Publication Number Publication Date
HK1039745A1 true HK1039745A1 (zh) 2002-05-10

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100158.6A HK1039745A1 (zh) 1998-10-16 1999-10-12 用於改善识别的非典型抗精神病药和乙酰胆碱酯酶

Country Status (20)

Country Link
EP (1) EP1121131A2 (fr)
JP (1) JP2002527469A (fr)
KR (1) KR20010072878A (fr)
CN (1) CN1367697A (fr)
AU (1) AU6472799A (fr)
BG (1) BG105302A (fr)
BR (1) BR9914419A (fr)
CA (1) CA2345767A1 (fr)
EE (1) EE200100136A (fr)
HK (1) HK1039745A1 (fr)
HR (1) HRP20010262A2 (fr)
HU (1) HUP0103781A3 (fr)
ID (1) ID28441A (fr)
IL (1) IL142588A0 (fr)
NO (1) NO20011403L (fr)
PL (1) PL348107A1 (fr)
SK (1) SK4592001A3 (fr)
TR (1) TR200101082T2 (fr)
WO (1) WO2000023057A2 (fr)
ZA (1) ZA200103081B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
CA2463158C (fr) * 2001-10-30 2013-07-30 Novartis Ag Preparations de depot d'iloperidone et de polymere en etoile
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
WO2006065233A1 (fr) * 2004-12-10 2006-06-22 Abbott Laboratories Dérivés polycycliques de quinuclidine substitués par un bicyclohétérocycle condensé
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
EP2091948B1 (fr) 2006-11-30 2012-04-18 Probiodrug AG Nouveaux inhibiteurs de glutaminylcyclase
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX2007008642A (es) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias.
EA037187B1 (ru) 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
CA2789440C (fr) 2010-03-10 2020-03-24 Probiodrug Ag Inhibiteurs heterocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
AU2016268096B2 (en) 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3461819B1 (fr) 2017-09-29 2020-05-27 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020327A1 (fr) * 1991-05-14 1992-11-26 Ernir Snorrason Traitement des etats de fatigue a l'aide d'inhibiteurs de cholinesterase
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
CA2300148C (fr) * 1997-08-11 2009-06-23 University Of South Florida Antagonistes de la nicotine destines a des troubles neuropsychiatriques sensibles a la nicotine
CA2328197C (fr) * 1998-04-14 2007-11-20 The General Hospital Corporation Methodes de traitement de troubles neuropsychiatriques

Also Published As

Publication number Publication date
AU6472799A (en) 2000-05-08
KR20010072878A (ko) 2001-07-31
HUP0103781A2 (hu) 2002-03-28
WO2000023057A3 (fr) 2000-07-27
EP1121131A2 (fr) 2001-08-08
ZA200103081B (en) 2002-07-12
HUP0103781A3 (en) 2003-09-29
IL142588A0 (en) 2002-03-10
NO20011403D0 (no) 2001-03-20
PL348107A1 (en) 2002-05-06
WO2000023057A2 (fr) 2000-04-27
SK4592001A3 (en) 2001-12-03
BG105302A (en) 2001-11-30
ID28441A (id) 2001-05-24
CA2345767A1 (fr) 2000-04-27
EE200100136A (et) 2002-06-17
TR200101082T2 (tr) 2001-09-21
BR9914419A (pt) 2001-06-26
JP2002527469A (ja) 2002-08-27
CN1367697A (zh) 2002-09-04
NO20011403L (no) 2001-03-20
HRP20010262A2 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
WO2000023057A3 (fr) Therapie visant a ameliorer la cognition
CA2370565A1 (fr) Compositions pharmaceutiques contenant de la vitamine d pour application cutanee
CA2326756A1 (fr) Compositions pharmaceutiques contenant des composes ameliorant l'absorption des principes actifs
CA2183972A1 (fr) Derives de l'oxazolidinone et compositions pharmaceutiques contenant ces derniers
CA2356380A1 (fr) Effets immunosuppresseurs de derives de la pteridine
CA2317044A1 (fr) Medicament pour maladies neurodegeneratives
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
WO1999063977A3 (fr) Composition pharmaceutique destinee a traiter ou prevenir les troubles du sommeil
MXPA02000437A (es) Composicion para el tratamiento de trastornos de secrecion externa.
CA2214026A1 (fr) Compositions pharmaceutiques comprenant des inhibiteurs de la monoamine oxydase b
BR0012696A (pt) Composição oftálmica
MXPA02002452A (es) Agentes preventivos y terapeuticos para enfermedades de oftalmicas.
HUP0204049A3 (en) Compositions of combined active ingredients for treating glaucoma
EP2138175A3 (fr) Formulations comprenant du valsartan pour traiter le diabète ou la microalbuminurie
IL159412A0 (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes
CA2282279A1 (fr) Atropisomeres de 3-heteroaryl-4(3h)-quinazolinones pour le traitement des troubles neurodegeneratifs et des troubles lies a un traumatisme du systeme nerveux central
WO1999061010A3 (fr) TRAITEMENT DE L'INFERTILITE PAR DES COMPOSES STIMULANT LA PRODUCTION D'AMPc, SEULS OU ASSOCIES A AU MOINS UN COMPOSE STIMULANT LA MEIOSE
TW354762B (en) Agent for prophylaxis or treatment of cataract
CA2192822A1 (fr) Utilisation d'agents immunosuppresseurs dans le traitement de la schizophrenie
GR3032301T3 (en) N-hydroxyureas as antiinflammatory agents
EP0842663A4 (fr) Preparations ophtalmiques
WO2001005386A3 (fr) Composition pharmaceutique utile dans le traitement de bourdonnement d'oreilles et de surdite
EP1121932A4 (fr) Medicaments pour maladies oculaires
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation